The present study describes a pharmacology study with safety measurements for our clinical candidate vector, AAVhu37.E03.TTR.hFVIIIco-SQ.PA75, in FVIII KO mice to determine the minimally effective dose (MED) and to support the initiation of a Phase 1 clinical trial in patients with hemophilia A. This evidence concerns the gene TTR and hemophilia A.